# **Special Issue**

# New Insights on Drug Design, Delivery and Targeting in Neurodegeneration

## Message from the Guest Editors

Neurodegenerative diseases represent a heterogenous group of disorders characterized by progressive degeneration and death of neuronal populations. This problem is even more fundamental as the available therapies remain fairly limited and mainly focusing on symptoms relief. Thus, the development of novel drug candidates, based on state-of-the-art chemistry methodologies and/or sparsely explored chemical substances, could help to identify lead compounds with potential pharmaceutical application. On the other hand, the lack of drug efficacy in neurodegeneration treatment comes from a compromised drug delivery to their target sites. Thus, the development of cutting-edge drug delivery systems and approaches would add substantial advance in neurodegeneration treatment. In this special issue we are interested in reviews and original articles describing novel chemical design-based drug candidates and improved delivery systems to target sites with potential to deal with neurodegeneration, drug design and discovery drug delivery drug targeting neurodegeneration new therapeutic strategies in vitro models of neurodegeneration

## **Guest Editors**

## Dr. Renata Silva

 Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal
 UCIBIO—Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal

### Dr. Daniel José Barbosa

- Associate Laboratory i4HB—Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal
- 2. UCIBIO—Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal

# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/111102

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics



## Deadline for manuscript submissions

closed (31 July 2023)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

## **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

